These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 38977231)

  • 1. Unveiling the regulatory mechanism of nimotuzumab on PD-L1 expression in head and neck squamous cell carcinoma patients: Implications for enhanced anticancer treatment strategies.
    Hu M; Tang B; Dai Y; Zhao X
    Cell Signal; 2024 Sep; 121():111290. PubMed ID: 38977231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PD-L1 and MRN synergy in platinum-based chemoresistance of head and neck squamous cell carcinoma.
    Shen B; Huang D; Ramsey AJ; Ig-Izevbekhai K; Zhang K; Lajud SA; O'Malley BW; Li D
    Br J Cancer; 2020 Mar; 122(5):640-647. PubMed ID: 31853007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interferon-alpha enhances the antitumour activity of EGFR-targeted therapies by upregulating RIG-I in head and neck squamous cell carcinoma.
    Ma H; Jin S; Yang W; Zhou G; Zhao M; Fang S; Zhang Z; Hu J
    Br J Cancer; 2018 Feb; 118(4):509-521. PubMed ID: 29348488
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma.
    Hirata-Nozaki Y; Ohkuri T; Ohara K; Kumai T; Nagata M; Harabuchi S; Kosaka A; Nagato T; Ishibashi K; Oikawa K; Aoki N; Ohara M; Harabuchi Y; Uno Y; Takei H; Celis E; Kobayashi H
    J Transl Med; 2019 Jun; 17(1):207. PubMed ID: 31221178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brusatol improves the efficacy of an anti-mouse-PD-1 antibody via inhibiting programmed cell death 1 ligand 1 expression in a murine head and neck squamous cell carcinoma model.
    Wu Y; Zhang G; Yin P; Wen J; Su Y; Zhang X
    Arch Oral Biol; 2024 Oct; 166():106043. PubMed ID: 38968906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel IFNα-induced long noncoding RNA negatively regulates immunosuppression by interrupting H3K27 acetylation in head and neck squamous cell carcinoma.
    Ma H; Chang H; Yang W; Lu Y; Hu J; Jin S
    Mol Cancer; 2020 Jan; 19(1):4. PubMed ID: 31907020
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploration of Immune-Modulatory Effects of Amivantamab in Combination with Pembrolizumab in Lung and Head and Neck Squamous Cell Carcinoma.
    Lim SM; Kang SS; Kim DK; Lee SH; Synn CB; Baek S; Yang SM; Han YJ; Kim MH; Han H; Na K; Kim YT; Yun MR; Kim JH; Byeon Y; Kim YS; Lee JB; Hong MH; Curtin JC; Patel B; Bergiers I; Pyo KH; Cho BC
    Cancer Res Commun; 2024 Jul; 4(7):1748-1764. PubMed ID: 38916448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cisplatin Alters Antitumor Immunity and Synergizes with PD-1/PD-L1 Inhibition in Head and Neck Squamous Cell Carcinoma.
    Tran L; Allen CT; Xiao R; Moore E; Davis R; Park SJ; Spielbauer K; Van Waes C; Schmitt NC
    Cancer Immunol Res; 2017 Dec; 5(12):1141-1151. PubMed ID: 29097421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune checkpoint inhibitor monotherapy is sufficient to promote microenvironmental normalization via the type I interferon pathway in PD-L1-expressing head and neck cancer.
    Jang JY; Lee BS; Huang M; Seo C; Choi JH; Shin YS; Woo HG; Kim CH
    Mol Oncol; 2024 Aug; 18(8):1923-1939. PubMed ID: 38511232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic targeting of thioredoxin reductase 1 causes ferroptosis while potentiating anti-PD-1 efficacy in head and neck cancer.
    Hsieh MS; Ling HH; Setiawan SA; Hardianti MS; Fong IH; Yeh CT; Chen JH
    Chem Biol Interact; 2024 May; 395():111004. PubMed ID: 38636790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulation of cisplatin-resistant head and neck squamous cell carcinoma by the SRC/ETS-1 signaling pathway.
    Yang Z; Liao J; Carter-Cooper BA; Lapidus RG; Cullen KJ; Dan H
    BMC Cancer; 2019 May; 19(1):485. PubMed ID: 31118072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulation of programmed-death ligand in the human head and neck squamous cell carcinoma microenvironment is mediated through matrix metalloproteinase-mediated proteolytic cleavage.
    Hira-Miyazawa M; Nakamura H; Hirai M; Kobayashi Y; Kitahara H; Bou-Gharios G; Kawashiri S
    Int J Oncol; 2018 Feb; 52(2):379-388. PubMed ID: 29345283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PD-L2 glycosylation promotes immune evasion and predicts anti-EGFR efficacy.
    Xu Y; Gao Z; Hu R; Wang Y; Wang Y; Su Z; Zhang X; Yang J; Mei M; Ren Y; Li M; Zhou X
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34697216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy.
    Zandberg DP; Algazi AP; Jimeno A; Good JS; Fayette J; Bouganim N; Ready NE; Clement PM; Even C; Jang RW; Wong S; Keilholz U; Gilbert J; Fenton M; Braña I; Henry S; Remenar E; Papai Z; Siu LL; Jarkowski A; Armstrong JM; Asubonteng K; Fan J; Melillo G; Mesía R
    Eur J Cancer; 2019 Jan; 107():142-152. PubMed ID: 30576970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma.
    Haddad RI; Seiwert TY; Chow LQM; Gupta S; Weiss J; Gluck I; Eder JP; Burtness B; Tahara M; Keam B; Kang H; Muro K; Albright A; Mogg R; Ayers M; Huang L; Lunceford J; Cristescu R; Cheng J; Mehra R
    J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35217573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Melatonin inhibits EMT and PD-L1 expression through the ERK1/2/FOSL1 pathway and regulates anti-tumor immunity in HNSCC.
    Luo X; Chen Y; Tang H; Wang H; Jiang E; Shao Z; Liu K; Zhou X; Shang Z
    Cancer Sci; 2022 Jul; 113(7):2232-2245. PubMed ID: 35298069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nimotuzumab increases the anti-tumor effect of photodynamic therapy in an oral tumor model.
    Bhuvaneswari R; Ng QF; Thong PS; Soo KC
    Oncotarget; 2015 May; 6(15):13487-505. PubMed ID: 25918252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fibroblast growth factor receptor 3-mediated reactivation of ERK signaling promotes head and neck squamous cancer cell insensitivity to MEK inhibition.
    Ban MJ; Byeon HK; Yang YJ; An S; Kim JW; Kim JH; Kim DH; Yang J; Kee H; Koh YW
    Cancer Sci; 2018 Dec; 109(12):3816-3825. PubMed ID: 30343534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HGF-Induced PD-L1 Expression in Head and Neck Cancer: Preclinical and Clinical Findings.
    Boschert V; Teusch J; Aljasem A; Schmucker P; Klenk N; Straub A; Bittrich M; Seher A; Linz C; Müller-Richter UDA; Hartmann S
    Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33233528
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In Situ PD-L1 Expression in Oral Squamous Cell Carcinoma Is Induced by Heterogeneous Mechanisms among Patients.
    Kondo Y; Suzuki S; Ono S; Goto M; Miyabe S; Ogawa T; Tsuchida H; Ito H; Takahara T; Satou A; Tsuzuki T; Yoshikawa K; Ueda R; Nagao T
    Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35456895
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.